Xeris Biopharma Holdings, Inc. XERS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s interest expense?
- Xeris Biopharma Holdings, Inc. (XERS) reported interest expense of $6.88M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s interest expense changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s interest expense decreased by 5.8% year-over-year, from $7.31M to $6.88M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s interest expense has grown at a 41.9% compound annual growth rate (CAGR), from $7.18M to $29.08M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.